SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001479290-22-000082
Filing Date
2022-08-09
Accepted
2022-08-09 17:13:38
Documents
78
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rvnc-20220630.htm   iXBRL 10-Q 2253448
2 EX-31.1 rvncq222exhibit311.htm EX-31.1 8774
3 EX-31.2 rvncq222exhibit312.htm EX-31.2 8786
4 EX-32.1 rvncq222exhibit321.htm EX-32.1 6482
5 EX-32.2 rvncq222exhibit322.htm EX-32.2 6534
  Complete submission text file 0001479290-22-000082.txt   9103537

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20220630.xsd EX-101.SCH 53815
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20220630_cal.xml EX-101.CAL 104626
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20220630_def.xml EX-101.DEF 251982
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20220630_lab.xml EX-101.LAB 657552
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20220630_pre.xml EX-101.PRE 427996
72 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20220630_htm.xml XML 1667289
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36297 | Film No.: 221149401
SIC: 2834 Pharmaceutical Preparations